McKesson Reports Strong Growth and Raises EPS Guidance

McKesson Corporation ( (MCK) ) has released its Q3 earnings. Here is a breakdown of the information McKesson Corporation presented to its investors.

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes through partnerships with biopharma companies, care providers, pharmacies, and more, impacting virtually every aspect of healthcare. In its fiscal 2025 third quarter earnings report, McKesson Corporation reported significant growth with consolidated revenues reaching $95.3 billion, marking an 18% increase, and adjusted earnings per diluted share increasing by 4% to $8.03. Key financial highlights include an 18% increase in consolidated revenues and a 57% rise in earnings per diluted share, driven primarily by growth in the U.S. Pharmaceutical segment and strategic acquisitions and divestitures. The company has also signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC, and completed the sale of its Canada-based retail businesses. Looking forward, McKesson has raised its fiscal 2025 adjusted earnings per diluted share guidance, reflecting a growth outlook of 19% to 20% compared to the previous year, as it continues to focus on its enterprise growth strategy and expansion in the oncology and biopharma services sectors.